Literature DB >> 19132788

Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors.

Marta Vadacca1, Domenico Margiotta, Amelia Rigon, Fabio Cacciapaglia, Giusy Coppolino, Antonio Amoroso, Antonella Afeltra.   

Abstract

OBJECTIVE: To study concentrations of adipokines in patients with systemic lupus erythematosus (SLE) and the relationship among adipokines, the metabolic syndrome (MeS), and cardiovascular disease (CVD) risk factors.
METHODS: We enrolled 50 SLE patients and 26 controls, all women. Leptin, resistin, visfatin, and adiponectin were measured by commercial ELISA kits.
RESULTS: MeS prevalence was increased among subjects with SLE. Leptin levels were higher in patients with SLE than controls. Among SLE patients, independent determinants of leptin were insulin levels (p < 0.0001), triglycerides (p = 0.03), body mass index (p = 0.02), corticosteroid dosage (p = 0.02), and SLE Disease Activity Index (p = 0.005). Other adipokines did not differ between SLE patients and controls.
CONCLUSION: Leptin was increased in SLE patients and could play a role in SLE-related cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132788     DOI: 10.3899/jrheum.080503

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

1.  Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants.

Authors:  Alimohammad Fatemi; Azadeh Ghanbarian; Zahra Sayedbonakdar; Mehdi Kazemi; Abbas Smiley
Journal:  Clin Rheumatol       Date:  2018-01-05       Impact factor: 2.980

2.  Serum adipokine levels and associations with patient-reported fatigue in systemic lupus erythematosus.

Authors:  Mary A Mahieu; Grace E Ahn; Joan S Chmiel; Dorothy D Dunlop; Irene B Helenowski; Pamela Semanik; Jing Song; Susan Yount; Rowland W Chang; Rosalind Ramsey-Goldman
Journal:  Rheumatol Int       Date:  2018-01-04       Impact factor: 2.631

3.  Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and coronary calcification.

Authors:  Joshua F Baker; Megan Morales; Mohammed Qatanani; Andrew Cucchiara; Eleni Nackos; Mitchell A Lazar; Karen Teff; Joan Marie von Feldt
Journal:  J Rheumatol       Date:  2011-09-01       Impact factor: 4.666

4.  Resistin as a potential marker of renal disease in lupus nephritis.

Authors:  J Hutcheson; Y Ye; J Han; C Arriens; R Saxena; Q-Z Li; C Mohan; T Wu
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

Review 5.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

6.  Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age.

Authors:  Marta Maria das Chagas Medeiros; Ídila Mont'Alverne Xavier de Oliveira; Ádilla Thaysa Mendes Ribeiro
Journal:  Rheumatol Int       Date:  2015-07-07       Impact factor: 2.631

7.  Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus.

Authors:  Marta Vadacca; Enrico M Zardi; Domenico Margiotta; Amelia Rigon; Fabio Cacciapaglia; Luisa Arcarese; Francesca Buzzulini; Antonio Amoroso; Antonella Afeltra
Journal:  Intern Emerg Med       Date:  2011-11-30       Impact factor: 3.397

8.  Visfatin levels and intima-media thicknesses in rheumatic diseases.

Authors:  Metin Ozgen; Suleyman Serdar Koca; Kader Aksoy; Necati Dagli; Bilal Ustundag; Ahmet Isik
Journal:  Clin Rheumatol       Date:  2010-12-17       Impact factor: 2.980

9.  Management of cardiovascular complications in systemic lupus erythematosus.

Authors:  Carly Skamra; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

Review 10.  Association between leptin and systemic lupus erythematosus.

Authors:  Wang-Dong Xu; Min Zhang; Yu-Jing Zhang; Shan-Shan Liu; Hai-Feng Pan; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2013-05-11       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.